Indication for Infliximab Expanded in RA Patients

WASHINGTON (Reuters Health) Feb 28 – Johnson & Johnson company Centocor Inc. said on Thursday that it has received approval from the US Food and Drug Administration (FDA) to market Remicade (infliximab) for the improvement of physical function in patients with rheumatoid arthritis (RA), when used in combination with methotrexate.
Remicade is a monoclonal antibody that was designed to target and bind to the tumor necrosis factor alpha (TNF-a). The FDA previously approved it to inhibit the progression of structural damage and reduce the signs and symptoms of RA, when used in combination with methotrexate….

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים